Meeting
2019 ASCO Annual Meeting
Allogeneic hematopoietic stem cell transplantation contributes to eradication of minimal residual disease in adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with dasatinib.
Authors
Jeremy Chang
University of Southern California + LA County Medical Center Internal Medicine Residency, Los Angeles, CA
Jeremy Chang , Mojtaba Akhtari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7024)
DOI
10.1200/JCO.2019.37.15_suppl.7024
Abstract #
7024
Poster Bd #
399
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
First Author: Nicholas James Short
Poster
2019 ASCO Annual Meeting
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.
First Author: Elias Jabbour
Poster
2018 ASCO Annual Meeting
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
First Author: Wendy Stock
Poster
2016 ASCO Annual Meeting
Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
First Author: Koji Sasaki